Dr Reddy's Laboratories

RDY · NATIONAL

$13.21−$0.02 (−0.15%)TodayMarket closed ·
Prev close $13.23

About RDY

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 26,944 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

Employees
27,527
Headquarters
Hyderabad, Telangana
Listed
Jan 1, 1986
Sector
Health Care
Industry
Pharmaceuticals

RDY key statistics

Market cap
1.03T
Price-earnings ratio
31.50
Dividend yield
0.64%
Average volume
3.18M
Volume
3.91M
Open price
$13.52
High today
$13.57
Low today
$13.18
52 Week high
$15.67
52 Week low
$11.36

Dr Reddy's Laboratories (RDY) at a glance

Dr Reddy's Laboratories (RDY) last traded at $13.21, with a market cap of 1.03T, a price-to-earnings ratio of 31.50 and a dividend yield of 0.64%.

Today the stock has traded between $13.18 and $13.57. The current price is 0.3% above the day's low and 2.7% below its high.

Volume so far is 3.91M shares, above the average of 3.18M shares a day.

Over the past year Dr Reddy's Laboratories has ranged from $11.36 to $15.67, and now sits 43% of the way up that range.

The average analyst price target is $13.92, 5.4% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 39 analystsAvg $13.92
Low
$11.20
Now
$13.21
High
$19.50

RDY news

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY

  • Press releaseBusiness Wire

    Securities Fraud Investigation Into Dr. Reddy’s Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • Press releaseBusiness Wire

    Dr. Reddy’s Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.